Control and Augmentation of Long-Term Plasmid Transgene Expression <i>In Vivo</i> in Murine Muscle Tissue and <i>Ex Vivo</i>  in Patient Mesenchymal
Tissue

<table>Duration of plasmid-based CMV promoter activity <i>in vivo</i> in liver and muscle. pCMV-luc was delivered to liver and thigh muscle (<svg height="10.9125" id="M2" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 42.912498 10.9125" width="42.912498" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="27.969212" y="0">0</tspan>
</text>
</g>
</g>
</svg>) by electroporation and luminescence analysed <i>in vivo</i> over time using IVIS live whole body imaging. CMV activity in liver is initially high but reduced to background level by day 14. A gross reduction in expression over time was not apparent in muscle.</table>

BioMed Research International

fig2

Figure 2

Figure 2: Control and Augmentation of Long-Term Plasmid Transgene Expression <i>In Vivo</i> in Murine Muscle Tissue and <i>Ex Vivo</i>  in Patient Mesenchymal
Tissue 

Figure 2 | Control and Augmentation of Long-Term Plasmid Transgene Expression In Vivo in Murine Muscle Tissue and Ex Vivo  in Patient Mesenchymal
Tissue 

BioMed Research International

Control and Augmentation of Long-Term Plasmid Transgene Expression In Vivo in Murine Muscle Tissue and Ex Vivo in Patient Mesenchymal Tissue

Figure 2